SWOG S1007试验中入组的有利风险淋巴结阳性乳腺癌患者的放疗使用与局部区域复发发生率
该研究为SWOG S1007试验的二次分析,纳入4871例激素受体阳性、ERBB2阴性且Oncotype DX复发评分≤25的乳腺癌患者,评估区域淋巴结照射(RNI)的使用模式及局部区域复发(LRR)发生率。中位随访6.1年,接受RNI者占59.0%,各局部治疗组5年LRR累积发生率均较低,无化疗组亦然。无侵袭性疾病生存(IDFS)与是否接受RNI无显著差异。
要点
- 在生物学有利的N1乳腺癌中,RNI使用存在分歧,59.0%接受放疗的患者接受了RNI。
- 各局部治疗组5年LRR累积发生率均低,未接受RNI者亦低。
- IDFS与是否接受RNI无显著差异,绝经前HR 1.03,绝经后HR 0.85。
核心结论
- 在生物学有利的N1乳腺癌中,RNI使用存在分歧,即使未接受RNI的患者LRR发生率也低。
- 无病生存与是否接受RNI无关;对于类似S1007试验入组患者,省略化疗并非使用RNI的独立指征。
研究设计与样本
- SWOG S1007试验的二次分析,纳入激素受体阳性、ERBB2阴性且Oncotype DX 21基因乳腺复发评分≤25的患者,随机接受单纯内分泌治疗或化疗后内分泌治疗。
- 前瞻性收集4871例在不同机构治疗患者的放疗信息,数据分析时间为2022年6月至2023年4月。
主要发现
- 4871例女性患者(中位年龄57岁,范围18-87岁)中,3947例(81.0%)报告接受了放疗。
- 3852例接受放疗且有完整靶区信息的患者中,2274例(59.0%)接受了RNI。
- 中位随访6.1年,5年LRR累积发生率:保乳手术加放疗加RNI为0.85%;保乳手术加放疗无RNI为0.55%;乳房切除术后放疗为0.11%;乳房切除术后无放疗为1.7%。
- 在分配至单纯内分泌治疗(无化疗)组内也观察到 similarly low 的LRR。
- IDFS率与是否接受RNI无差异(绝经前:HR 1.03,95%CI 0.74-1.43,P=0.87;绝经后:HR 0.85,95%CI 0.68-1.07,P=0.16)。
关键数值与推荐
- RNI定义为至少针对锁骨上区域。
- LRR累积发生率按接受的局部区域治疗计算。
- IDFS分析调整了绝经状态、治疗组、复发评分、肿瘤大小、受累淋巴结和腋窝手术。
- 放疗信息在随机化后第一年记录,生存分析以1年为界标起始。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Little is known about regional nodal irradiation (RNI) practice patterns or rates of locoregional recurrence (LRR) with and without RNI in patients with limited nodal disease and favorable biology treated with modern surgical and systemic therapy, including approaches that de-escalate those latter treatments. OBJECTIVE: To investigate how often patients with low-recurrence score breast cancer with 1 to 3 nodes involved receive RNI, incidence and predictors of LRR, and associations between locoregional therapy and disease-free survival. DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of the SWOG S1007 trial, patients with hormone receptor-positive, ERBB2-negative breast cancer, and a Oncotype DX 21-gene Breast Recurrence Score assay result of no more than 25, were randomized to endocrine therapy alone vs chemotherapy then endocrine therapy. Prospectively collected radiotherapy information was collected from 4871 patients treated in diverse settings. Data were analyzed June 2022 to April 2023. EXPOSURE: Receipt of RNI (targeting at least the supraclavicular region). MAIN OUTCOME(S) AND MEASURE(S): Cumulative incidence of LRR was calculated by locoregional treatment received. Analyses were assessed for associations between invasive disease-free survival (IDFS) and locoregional therapy, adjusted for menopausal status, treatment group, recurrence score, tumor size, nodes involved, and axillary surgery. Radiotherapy information was recorded in the first year after randomization, so survival analyses were landmarked as starting at 1 year among those still at risk. RESULTS: Of 4871 female patients (median [range] age, 57 [18-87] years) with radiotherapy forms, 3947 (81.0%) reported radiotherapy receipt. Of 3852 patients who received radiotherapy and had complete information on targets, 2274 (59.0%) received RNI. With a median follow-up of 6.1 years, the cumulative incidence of LRR by 5 years was 0.85% among patients who received breast-conserving surgery and radiotherapy with RNI; 0.55% after breast-conserving surgery with radiotherapy without RNI; 0.11% after mastectomy with postmastectomy radiotherapy; and 1.7% after mastectomy without radiotherapy. Similarly low LRR was observed within the group assigned to endocrine therapy without chemotherapy. The rate of IDFS did not differ by RNI receipt (premenopausal: hazard ratio [HR], 1.03; 95% CI, 0.74-1.43; P = .87; postmenopausal: HR, 0.85; 95% CI, 0.68-1.07; P = .16). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a clinical trial, RNI use was divided in the setting of biologically favorable N1 disease, and rates of LRR were low even in patients who did not receive RNI. Disease-free survival was not associated with RNI receipt; omission of chemotherapy among patients similar to those enrolled in the S1007 trial is not an independent indication for use of RNI.
引用
- Jagsi R, Barlow WE, Woodward WA, et al. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol. 2023. PMID: 37410451. doi:10.1001/jamaoncol.2023.1984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。